MissionIR Articles

Biotechnology company VistaGen Therapeutics is blazing trails with advances in pluripotent stem cell technology, operating on the belief that “Better Cells Make Better Medicine.” Human Clinical Trials in a Test Tube is the company’s versatile…

VistaGen Therapeutics, a California-based biotechnology company, is addressing the need to bring effective treatments to market while reducing the time and cost traditionally needed to do so. By leveraging its Human Clinical Trials in a…

With diseases such as Alzheimer’s, type 2 diabetes, and rheumatoid arthritis on the rise, there is a growing need for new and more effective treatments. But as an editorial by the Washington Post on new…

The U.S. Food and Drug Administration has a low tolerance for drug candidates with safety risks; countless potential new drugs candidates fail in preclinical or clinical trials due to safety concerns, costing pharmaceutical companies billions…

VistaGen Therapeutics is a California-based biotechnology company that specializes in the application of human pluripotent stem cell (hPSC) technology for drug rescue, including predictive toxicology and drug metabolism screening. The company’s hPSC technology platform, Human…

In calendar year 2013, the U.S. FDA’s Center for Drug Evaluation and Research (CDER) approved 27 novel new medicines (NMEs) approved under New Drug Applications (NDAs) and Biologics License Applications (BLAs). This comes from a…

There’s a pivotal shift taking place the pharmaceutical industry, one that bridges the gap between the company with an $80 billion market cap and heavy cash flow and the one with an $8 million market…

The U.S. pharmaceutical industry is facing a “drug discovery and development crisis,” says small-cap biotech VistaGen Therapeutics, evidenced by the fact that while the pharmaceutical industry in 2012 invested nearly $49 billion in R&D, a…

Human Clinical Trials in a Test Tube™ — sounds like something out of a science fiction movie, but as it turns out, this is science reality. VistaGen Therapeutics is the developer of this versatile human…

Each year, the U.S. pharmaceutical industry invests billions of dollars in research and development of novel drugs, but many drugs never reach the final stage of FDA approval. For the pharmaceutical companies engaging in the…

Biotechnology company VistaGen Therapeutics is putting humans first with Human Clinical Trials in a Test Tube. This human pluripotent stem cell (hPSC) technology platform has been developed to provide clinically relevant predictions of potential toxicity…

VistaGen Therapeutics employs the expertise of company co-founder and renowned Canadian stem cell scientist Dr. Gordon Keller, as well as co-founder, president, and chief scientific officer Dr. Ralph Snodgrass. Human Clinical Trials in a Test…

Antidepressants are the most commonly consumed class of therapeutics in the United States, prescribed to more than 270 million patients each year. Ketamine, an NMDA receptor antagonist used as an anesthetic in human and veterinary…

VistaGen is a biotech company applying its human pluripotent stem cell (hPSC) technology for drug rescue, including predictive toxicology and drug metabolism screening. The company’s human pluripotent stem cell (hPSC) technology platform, Human Clinical Trials…

With grant funding from the U.S. National Institutes of Health (NIH), biotechnology company VistaGen Therapeutics, Inc. has successfully completed Phase 1 development of AV-101, an orally available small molecule prodrug candidate. AV-101 is targeted at…

VistaGen Therapeutics, a biotechnology company, is blazing new trails by looking to the past. The company has developed a pioneering stem cell technology platform that can give a second chance to potentially lifesaving drugs that…

VistaGen Therapeutics has developed a versatile human pluripotent stem cell (hPSC) technology platform based on the controlled differentiation of hPSCs into mature, non-transformed, human cells. The company’s goal is to integrate this hPSC technology with…

The limitations of current animal and in vitro cell culture testing have long been a stumbling block for pharmaceutical companies as they endeavor to develop new lifesaving drugs. A drug candidate that has shown great…

Approximately one-third of all potential new drug candidates are shelved in their late-stage development due to preclinical or clinical safety concerns. As a result, in the last decade the number of new drugs that are…

VistaGen Therapeutics has developed a unique stem cell technology platform called Human Clinical Trials in a Test Tube™ – it’s a fairly simple name representing a complex and innovative bioassay system with the ability to…